Filing Flows › Mirum Pharmaceuticals (MIRM) › Q3 2026
Mirum Pharmaceuticals (MIRM) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Mirum Pharmaceuticals (MIRM) reported revenue of $186M for the third quarter 2026 (Q3 2026), +40% from a year earlier and +5% from the quarter before. Operating margin was -32.2%, net loss $40.8M (22.0% of revenue).
Mirum Pharmaceuticals, Q3 2026: revenue $186M (+40% year over year), operating margin -32.2%, net loss $40.8M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $186M | +5% | +40% |
| Operating profit | −$59.7M | — | -2395% |
| Net earnings | −$40.8M | — | -1503% |
| Operating cash flow | −$4.3M | — | -111% |
What changed
Revenue was $185.7M in Q3 2026, up 40% year over year and up 5% from the previous quarter. Livmarli was the largest line at 72% of revenue. Livmarli added $41.2M year over year (up 45%), 78% of the total change.
Operating costs exceeded revenue by $59.7M, an operating margin of -32.2%. Total costs grew 88% against revenue growth of 40%. The fastest-growing cost line was Research & development (+151%). The quarter ended with a net loss of $40.8M, narrower than the previous quarter's $67.2M loss. Non-operating items added $19.5M, -49% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$4.3M. Non-cash charges added back $6.9M of depreciation and amortization and $33.3M of share-based compensation. Working capital and other items used $3.7M. Capital expenditures of $1.3M exceeded it, leaving free cash flow of −$5.6M.
Questions
What was Mirum Pharmaceuticals' revenue in the third quarter 2026?
Mirum Pharmaceuticals (MIRM) reported revenue of $186M for the third quarter 2026 (Q3 2026), +40% from a year earlier and +5% from the quarter before.
Was Mirum Pharmaceuticals profitable in the third quarter 2026?
Operating loss was $59.7M (-32.2% of revenue) and net loss $40.8M.